Clinical Trials Directory

Trials / Unknown

UnknownNCT04320303

CMV Infection and Immune Intervention After Transplantation

CMV Infection and Immune Intervention After Haploidentical Hematopoietic Stem Cell Transplantation

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Peking University People's Hospital · Academic / Other
Sex
All
Age
16 Years – 65 Years
Healthy volunteers
Accepted

Summary

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective or even the only way to cure blood malignant diseases. Cytomegalovirus (CMV) infection is a serious early complication of allo-HSCT. Its high incidence and poor prognosis can cause a series of terminal organ diseases such as CMV pneumonia, encephalitis, and enteritis,which seriously affecting the prognosis of patients post allo-HSCT. Our data show that rapid reconstruction of NK cells after transplantation can reduce the incidence of CMV infection. Patients with a rapid reconstruction of NKG2C after transplantation have a low CMV infection rate, and patients with strong secretion of IFN-gamma of NK after transplantation have low CMV infection. Our previous research showed that trophoblast cells transfected with IL-21 and 4-1BBL can achieve a large number of clinical-grade expansion of NK cells (mIL-21 / 4-1BBL NK cells), and mIL-21 / 4-1BBL NK cells It is safe to treat patients with minimal residual disease (MRD) positive AML after transplantation, and can induce MRD to turn negative. Previous studies have shown that adoptive infusion of expanded NK cells after haplotype transplantation is safe and can improve the functional reconstruction of NK cells. Therefore, we hypothesized that the infusion of NK cells can improve the antiviral capacity of NK cells, thereby effectively reducing the CMV infection. Incidence.

Conditions

Interventions

TypeNameDescription
BIOLOGICALexpanded NK cellsDonor derived expanded NK cells were infused to patients at around days 20±3d, and 27±3d post transplantation.

Timeline

Start date
2020-03-23
Primary completion
2021-12-31
Completion
2021-12-31
First posted
2020-03-24
Last updated
2021-06-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04320303. Inclusion in this directory is not an endorsement.